Peptides for Insulin Resistance: GLP-1, Tesamorelin & Emerging Compounds

Sarah arrived with a fasting glucose of 108 mg/dL, a HOMA-IR score of 3.9, and three years of dietary modifications that had produced nothing more than two pounds of weight loss and persistent fatigue. Her A1c was 5.9%. By every conventional measure, she was in prediabetes — and standard management had hit its ceiling.

What she needed was not a louder version of the same advice. She needed a different point of entry into the problem.

This article is about that different entry point: a class of signalling molecules — peptides — that researchers and clinicians are increasingly using to intervene in insulin resistance not by managing its downstream consequences, but by targeting the cellular and endocrine mechanisms that drive it upstream. Some are FDA-approved. Others are in active clinical trials. A few occupy a more ambiguous regulatory space that patients deserve to understand clearly before making any decisions.

What Is Insulin Resistance, Really?

Most patients who receive a prediabetes diagnosis have heard some version of the explanation that their cells "aren't listening to insulin anymore." It is not wrong, but it is clinically incomplete. Understanding what is actually happening — and where — is essential to evaluating why certain peptides show genuine promise against this condition.

The defect begins below the receptor

When insulin binds to its receptor, it initiates a signalling sequence through the phosphoinositide 3-kinase/Akt/mTOR pathway (PI3K/Akt/mTOR), which governs glucose transporter type 4 (GLUT4) translocation — the step that allows glucose to actually enter the cell. In insulin resistance, this cascade fails.

A landmark 2018 review in Physiological Reviews established that in most cases of acquired insulin resistance, the primary upstream driver is ectopic lipid accumulation — specifically diacylglycerol (DAG) in liver and skeletal muscle cells — which activates protein kinase C (PKC) isoforms that directly impair insulin receptor substrate (IRS-1) signalling. (Petersen & Shulman, 2018) The clinical implication: insulin resistance is not primarily a glucose problem. It is a lipid flux problem. The glucose disruption is downstream.

Simultaneously, chronic low-grade inflammation — mediated by NF-κB activation and elevated cytokines including TNF-α and IL-6 — independently impairs the insulin receptor via serine phosphorylation of IRS-1. (Samuel & Shulman, 2016) Visceral adipose tissue amplifies both pathways by releasing free fatty acids into the portal circulation and secreting pro-inflammatory adipokines, which is why visceral fat specifically — not body weight as a global variable — is the more precise metabolic target.

A third mechanism that most clinicians underaddress: impaired mitochondrial oxidative capacity in skeletal muscle. Reduced fatty acid oxidation leaves lipid intermediates to accumulate intracellularly, feeding the DAG-PKC loop above. This explains why lean, physically inactive patients can present with significant insulin resistance, and is one reason mitochondria-targeted peptides have drawn serious research attention.

The biomarkers that actually capture this

HOMA-IR (fasting glucose × fasting insulin ÷ 405) remains the most accessible proxy for hepatic insulin resistance. A value above 2.0 warrants attention; above 2.9, clinical intervention is appropriate in most frameworks. Fasting insulin alone is often more informative than glucose at earlier stages — glucose is buffered by compensatory hyperinsulinaemia for years before rising into the diagnostic range.

If you are trying to establish your own metabolic baseline before pursuing any intervention, Meto's Comprehensive Metabolic Panel includes fasting insulin, glucose, HOMA-IR, HbA1c, and a full lipid panel — the minimum required for meaningful clinical context.

Why Peptides? Targeting the Signalling Problem Directly

A peptide is a chain of amino acids — shorter than a full protein, typically under 50 amino acids — that functions as a biological signalling molecule. Insulin itself is a peptide. So is GLP-1, glucagon, GIP, and leptin. They are not supplements, not classical hormones in the endocrinological sense, and not small-molecule drugs. They are messengers that bind to specific receptors and initiate downstream cascades. Their therapeutic specificity — their selectivity for defined pathways — is both their advantage and the reason their risks are compound-specific rather than class-wide.

To understand the full mechanistic picture of how peptides communicate at the cellular level — including cAMP signalling and second-messenger cascades — Meto's primer on peptide cell signalling covers this in accessible detail.

Patients navigating this space need to hold three regulatory categories simultaneously: FDA-approved compounds (semaglutide, tirzepatide, tesamorelin) with defined safety profiles from Phase III trials; investigational compounds in active clinical trials (MOTS-c, retatrutide) where human data is accumulating; and research-grade peptides sold online without the manufacturing oversight that characterises the first two categories. That last distinction is not semantic — it carries direct safety implications covered in detail here.

GLP-1 Receptor Agonists: The Strongest Evidence Base in This Field

GLP-1 is an incretin hormone released from L-cells of the small intestine after meals. It potentiates insulin secretion from pancreatic beta cells in a glucose-dependent manner, suppresses glucagon secretion, slows gastric emptying, and reduces hepatic glucose output. Endogenous GLP-1 has a plasma half-life of about two minutes. Pharmaceutical analogues engineer around this limitation through structural modifications that resist DPP-4 degradation and extend the half-life to days or weeks.

Semaglutide: what the STEP programme actually shows

Semaglutide is a GLP-1 receptor agonist with approximately 94% homology to native GLP-1, modified with a C18 fatty diacid chain that enables albumin binding. The STEP-1 trial (N=1,961) demonstrated 14.9% mean body weight reduction over 68 weeks — but the metabolic finding more directly relevant here is that HOMA-IR and fasting insulin dropped significantly beyond what weight loss alone would predict, suggesting a direct insulin-sensitising effect at the receptor and hepatic levels. (Wilding et al., NEJM, 2021) The SUSTAIN-6 cardiovascular outcomes trial further demonstrated reductions in inflammatory markers, triglycerides, and hepatic steatosis markers — all upstream drivers of insulin resistance. (Marso et al., NEJM, 2016)

Tirzepatide: the dual-agonist advantage

Tirzepatide simultaneously agonises GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Co-agonism appears to alter adipose tissue lipid flux in a way that reduces ectopic fat deposition more specifically than single-receptor agents — likely through complementary mechanisms at adipocyte and hepatocyte levels. (Frias et al., NEJM, 2021) The SURMOUNT-1 trial (N=2,539) demonstrated up to 20.9% mean body weight reduction at the 15 mg dose, with parallel HOMA-IR improvements that substantially exceeded semaglutide's STEP-programme output. (Jastreboff et al., NEJM, 2022) The 2025 head-to-head SURMOUNT-5 trial confirmed tirzepatide's superior metabolic effect across multiple endpoints in non-diabetic patients with obesity.

For prediabetes specifically: reversal, not just delay

The SCALE Prediabetes trial demonstrated that 66.2% of participants on liraglutide (the predecessor GLP-1 agonist) reverted to normoglycaemia versus 36% on placebo at 160 weeks. (Le Roux et al., Lancet, 2017) Semaglutide and tirzepatide appear to produce comparable or superior reversal rates in prediabetes, though long-term RCT data in purely prediabetic populations remains an active research area. For insulin-resistant patients with prediabetes, GLP-1 therapy is not simply a glucose management tool — it is a mechanistic intervention with documented potential to halt and reverse progression.

Side effects and patient selection

Nausea, vomiting, and constipation affect approximately 20–40% of GLP-1 agonist users, particularly during dose titration. A personal or family history of medullary thyroid carcinoma or MEN2 is a contraindication. Pancreatitis and gallbladder disease signals exist and warrant monitoring. These are not agents to be started without clinical supervision and an active monitoring plan. Meto's clinical deep dive on semaglutide and tirzepatide covers the full evidence profile including what the data shows when patients discontinue therapy.

Tesamorelin: Visceral Fat and Hepatic Insulin Resistance

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that stimulates pituitary GH secretion. It received FDA approval in 2010 for excess abdominal fat in HIV-infected patients with lipodystrophy. Its off-label investigation in metabolic disease follows from a precise mechanistic rationale: visceral adipose tissue is the primary fat depot driving hepatic insulin resistance, and tesamorelin reduces it more specifically than most available interventions.

Visceral adipocytes drain their lipolytic output — free fatty acids — directly into the portal circulation, delivering substrate to the liver at rates that promote intrahepatic lipid accumulation and impaired hepatic insulin sensitivity. This explains why patients with normal BMI but high visceral-to-subcutaneous fat ratios can present with severe insulin resistance.

The 2007 NEJM trial by Falutz and colleagues demonstrated an 18% VAT reduction versus 5% on placebo at 26 weeks, with significant triglyceride improvements. (Falutz et al., NEJM, 2007) A subsequent NEJM trial by Stanley et al. in 2014 documented statistically significant reductions in liver fat fraction and improvements in hepatic insulin sensitivity directly relevant to the metabolic syndrome phenotype. (Stanley et al., NEJM, 2014) Tesamorelin's insulin sensitivity benefits appear mediated primarily through VAT reduction rather than direct receptor agonism — which limits its utility in insulin resistance without the visceral fat phenotype. It is not first-line broadly, but occupies a specific niche in the NAFLD/metabolic syndrome overlap that GLP-1 agonists do not fully address.

Emerging Compounds: MOTS-c, Humanin, and BPC-157

These compounds occupy a different position on the evidence hierarchy. The clinical data is either early-phase, limited in sample size, or — in BPC-157's case — primarily preclinical. This warrants clarity before proceeding.

MOTS-c is a 16-amino acid peptide encoded within the mitochondrial genome, discovered only in 2015. Its primary mechanism involves AMPK activation — the same energy-sensing pathway engaged by metformin and exercise — through translocation to the nucleus. In murine models, exogenous MOTS-c improved insulin sensitivity and reversed diet-induced glucose intolerance. A 2018 study demonstrated that circulating MOTS-c levels increase with acute exercise in humans, with younger and more active individuals showing higher baseline levels. (Lee et al., Cell Metabolism, 2015); (Kim et al., Cell Metabolism, 2018) Phase I human trials are underway, but no completed RCTs with metabolic endpoints in insulin-resistant patients have been published as of mid-2025. The mechanism is compelling. Clinical translation is not yet confirmed.

Humanin is a mitochondria-derived peptide, identified in 2001, initially for neuroprotective properties. It modulates hepatic gluconeogenesis and improves insulin sensitivity in rodent models. Observational data in humans shows circulating humanin levels decline with age and correlate inversely with metabolic syndrome components. (Muzumdar et al., Aging Cell, 2009) Intervention trials in insulin-resistant patients have not been completed.

BPC-157 is a synthetic pentadecapeptide derived from a gastric protein, with proposed mechanisms including gut-brain-liver axis modulation and nitric oxide pathway activation. Rodent model data on glucose metabolism is present. No published RCTs in humans with insulin resistance or metabolic syndrome endpoints exist as of this writing. The mechanistic science warrants continued investigation. The evidentiary basis to support clinical use in insulin resistance specifically is not yet there.

How These Compounds Compare

GLP-1 agonists are the most appropriate first consideration for insulin-resistant patients with excess body weight, elevated HbA1c approaching the prediabetes range, and no contraindications. Tesamorelin becomes relevant specifically in patients with documented visceral adiposity, elevated hepatic fat on imaging, elevated triglycerides, and a NAFLD/MASLD phenotype. MOTS-c and humanin are of legitimate scientific interest but are not yet candidates for clinical recommendation outside of trial settings.

What Patients With Insulin Resistance Should Know Before Pursuing Peptide Therapy

The lab work that must come first

No peptide protocol should be initiated without a metabolic baseline. The minimum panel includes fasting glucose, fasting insulin, HOMA-IR calculation, HbA1c, a full lipid panel (including non-HDL and triglycerides), and liver function tests. High-sensitivity CRP adds meaningful context on inflammatory burden. A HOMA-IR of 4.2 with elevated liver enzymes is a fundamentally different clinical picture than a HOMA-IR of 2.5 with normal liver function — both may carry the same prediabetes label, but they call for different interventions.

Peptides as adjunct, not replacement

The evidence base for GLP-1 agonists is built in populations simultaneously receiving nutritional counselling and physical activity guidance. The trials do not test the drug as a standalone replacement for lifestyle change. Skeletal muscle insulin sensitivity is driven substantially by GLUT4 transporter content — which responds to resistance training through pathways that GLP-1 agonists do not replicate. A peptide that suppresses appetite and improves hepatic glucose output does not rebuild the metabolic machinery that chronic inactivity has degraded. The framework that produces durable results is one where a peptide addresses the upstream signalling defect while lifestyle change rebuilds the tissue-level infrastructure.

Questions to raise with your clinician before starting

What is my HOMA-IR trend over the last 12–24 months? Does my phenotype match the population in which this compound was studied? What monitoring is in place during the first three to six months? What are the specific stopping criteria if my labs move in the wrong direction?

The unregulated peptide market: the risks are concrete

Independent assays of online peptide products have found concentration discrepancies of 30–90% from labelled amounts, bacterial endotoxin contamination, and in some cases entirely different compounds than those labelled. The clinical consequences of injecting an impure or mislabelled compound into a metabolically vulnerable patient are not theoretical. Meto's team covers the specific red flags and how to read a Certificate of Analysis here. For those beginning injectable protocols under clinical supervision, this step-by-step guide covers the procedural basics of safe home administration.

The Research Horizon

Retatrutide — a GLP-1/GIP/glucagon triple receptor agonist — produced up to 24.2% weight reduction at the highest dose in Phase II, exceeding any approved agent to date. The glucagon agonism component drives hepatic fatty acid oxidation, directly targeting the hepatic ectopic lipid component of insulin resistance rather than simply reducing caloric intake. (Jastreboff et al., NEJM, 2023) Phase III results are pending. If the safety profile holds, retatrutide would represent a meaningful advance specifically for the metabolic syndrome and NAFLD phenotypes.

Oral delivery technology remains the limiting factor for peptide therapy adoption. Oral semaglutide (Rybelsus) demonstrated feasibility using SNAC-mediated gastric absorption, but bioavailability remains approximately 1% of the injectable form. Next-generation nanoparticle and mucoadhesive formulations in development may eventually extend this to other compound classes, including investigational mitochondrial peptides. This is a medium-term horizon, not an immediate clinical reality.

The current state of mainstream clinical adoption of peptide medicine — including the regulatory pipeline and upcoming FDA advisory panels — is covered in depth on the Meto blog.

Meto's Take: What Root-Cause Metabolic Care Actually Requires

Meto's clinical team operates from a specific position: symptoms are not the starting point; the underlying biology is. Insulin resistance is almost never a single-pathway problem. The patients we see have usually been told their labs are "borderline" and sent home with instructions to eat less and move more — advice that is not wrong, but that addresses the problem at the wrong resolution.

Our approach begins with comprehensive biomarker assessment — not to label a condition, but to understand which mechanisms are dominant and which interventions are mechanistically matched to that individual. A patient with high visceral fat, elevated liver enzymes, and a HOMA-IR of 4.2 needs a different conversation than a patient with a HOMA-IR of 2.5, normal liver function, and a primary driver of hypothyroidism. Both may have been told they have "prediabetes."

Where GLP-1 receptor agonist therapy is clinically appropriate, Meto's physicians prescribe and monitor. Where the picture is more complex — NAFLD, PCOS, perimenopause-driven metabolic shift, thyroid-driven insulin resistance — we integrate the relevant evaluation and treatment accordingly. The PCOS & Hormonal Health Panel and the Longevity Panel extend the diagnostic picture for patients where metabolic dysfunction overlaps with hormonal disorder.

What we do not do is treat a HOMA-IR number in isolation, prescribe a peptide without a monitoring plan, or position any single compound as the solution to a multivariable problem.

If you are insulin resistant, prediabetic, or somewhere in the metabolic grey zone and looking for a clinical team that will actually examine the mechanisms with you:

Start a root-cause metabolic plan at Meto →

Key Takeaways

• Insulin resistance is driven primarily by ectopic lipid accumulation (DAG-PKC pathway), chronic inflammation (IRS-1 serine phosphorylation), and mitochondrial dysfunction — glucose dysregulation is downstream of all three.
• GLP-1 receptor agonists (semaglutide, tirzepatide) have the strongest clinical evidence for improving insulin sensitivity in overweight/prediabetic patients, with documented normoglycaemia reversal rates in large RCTs.
• Tesamorelin's most validated application in metabolic disease is visceral fat reduction with direct hepatic insulin sensitivity improvement — confirmed in two NEJM-published RCTs.
• MOTS-c and humanin have compelling mechanistic rationale and early positive data; they lack completed RCTs in insulin-resistant populations. BPC-157 lacks human intervention data for this indication.
• No peptide protocol is appropriate without a metabolic baseline, an ongoing monitoring plan, and a clinician who understands the compound being used.
• The unregulated online peptide market represents a genuine risk for purity, concentration, and contamination — sourcing matters as much as compound selection.
• Retatrutide (triple agonist) and improved oral delivery technology represent the most significant near-term advances in this field.